Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and expert in the field of drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich) and holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientist who discovered novel molecular mechanisms that can be exploited to prevent the development of resistance to cancer therapies.
EMMANUEL SAVIOZ, CFO
Emmanuel Savioz, Chief Financial Officer and co-founder, started his career in finance in New York as an investment banker in mergers and acquisitions handling large international transactions in consumer goods and healthcare. He then obtained an MBA from the Haas School of Business, University of California at Berkeley. Over the past 7 years, he has arranged CHF 70 million of equity financing. Emmanuel is a serial entrepreneur and has also co-founded the life science company Phi Pharma SA, the technology company Preciflex SA, the luxury watch company HYT SA.